Detection of c-erbB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Transitional cell carcinoma is the most common type of bladder cancer.
• The c-erbB-2 oncogene has been investigated for its role in various cancers.
• Understanding genetic alterations in bladder cancer is crucial for predicting patient outcomes.

Purpose of the Study:

• To retrospectively assess the prognostic significance of c-erbB-2 oncogene amplification in transitional cell bladder carcinomas.
• To determine if c-erbB-2 amplification predicts patient survival.
• To investigate changes in c-erbB-2 amplification during tumor recurrence and progression.

Main Methods:

• Competitive polymerase chain reaction (PCR) was used to quantify c-erbB-2 oncogene amplification.
• DNA was extracted from fresh tumor samples and formalin-fixed, paraffin-embedded tissues.
• Patient survival data was analyzed with a maximum follow-up of nine years.

Main Results:

• c-erbB-2 oncogene amplification was found in 26% of bladder tumors and significantly correlated with tumor grade (p < 0.0001).
• No statistical difference in survival probability was observed between patients with or without c-erbB-2 amplification.
• Tumor progression showed a limited increase in tumors with c-erbB-2 amplification, with no significant change in the degree of amplification.

Conclusions:

• c-erbB-2 amplification is associated with the differentiation grade of bladder tumors.
• The presence or degree of c-erbB-2 amplification does not appear to predict tumor progression, recurrence, or survival in advanced transitional cell bladder carcinoma.
• c-erbB-2 amplification in bladder cancer may be an epiphenomenon unrelated to clinical outcome.